Results 211 to 218 of about 13,157 (218)

Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients

Respiratory Medicine, 2011
Charles Fogarty, Anton Drollmann
exaly  

Aclidinium bromide, a novel long-acting muscarinic antagonist (LAMA)

2010
Amadeu Gavaldà, Esther Garcia-Gil
openaire   +1 more source

Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial

Lancet, The, 2017
Jørgen Vestbo, Alberto Papi, Massimo Corrádi   +2 more
exaly  

Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

Pulmonary Pharmacology and Therapeutics, 2010
D Cheung, T Overend
exaly  

Comparative Effectiveness of Long‐Acting Beta2‐Agonist Combined with a Long‐Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease

Pharmacotherapy, 2017
Min J Joo, Glen T Schumock
exaly  

Is Combination Long-acting Beta-Agonist and Long-acting Muscarinic Antagonist Therapy the Future of COPD Therapy?

Clinical Pulmonary Medicine, 2016
Michael J. Alexander, Dana Zappetti
openaire   +1 more source

Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs

Expert Opinion on Investigational Drugs, 2017
Neil E Ernst, Ralph J Panos
exaly  

Long-acting muscarinic antagonists for severe asthma: the perspective of SHARP clinicians

Airway pharmacology and treatment
Alessandro Marcon, Luigi Martinelli, Aruna T Bansal, Emmanuelle Berret, Apostolos Bossios, Ineta Grisle, Pierpaolo Marchetti, Celeste Porsbjerg, Stefania Principe, Florence Schleich, Svetlana Sergejeva, Jacob K Sont, Marco Caminati   +12 more
openaire   +1 more source